{"id":3692,"date":"2024-06-06T11:14:51","date_gmt":"2024-06-06T04:14:51","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=3692"},"modified":"2024-06-06T11:14:51","modified_gmt":"2024-06-06T04:14:51","slug":"regor-to-present-at-the-goldman-sachs-45th-annual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=3692","title":{"rendered":"Regor to Present at the Goldman Sachs 45th Annual Global Healthcare Conference"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">CAMBRIDGE, Mass.<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">June 5, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Regor Therapeutics Group, a clinical-stage global biopharmaceutical company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on\u00a0Thursday, June 13. Dr. <span class=\"xn-person\">Xiayang Qiu<\/span>, Founder and CEO, will represent the Company in a session scheduled at <span class=\"xn-chron\">11:20 am (Eastern Time)<\/span> on <span class=\"xn-chron\">June 13<\/span>.<\/p>\n<p><strong>About Regor Therapeutics Group<\/strong><\/p>\n<p>Regor Therapeutics Group (&#8220;Regor&#8221;) is founded in 2018 by a team of scientists with a proven track record in drug discovery and executive leadership covering full cycle of drug discovery and development. By leveraging its industry-leading core strength in rCARD\u2122 (Computer Accelerated Rational Discovery), Regor has completed 8 PCCs inhouse, with 5 INDs filed, validating Regor&#8217;s highly efficient ecosystem for accelerated discovery of innovative therapeutic agents.<\/p>\n<p>Regor&#8217;s in-house pipeline encompasses leading assets in metabolism, oncology and auto-immunity, with two leading assets: 1) RGT-075, an orally bioavailable small molecule GLP1R full agonist with best-in-class potential for obesity &amp; beyond; and 2) RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+\/HER2- breast cancer patients.<\/p>\n<p>With a strong focus on excellence in pharmaceutical research and global competitiveness, Regor aspires to build a world-class innovation engine that promotes a winning culture of scientific excellence, strong teamwork driven by results and delivery with shared accountability and successes.<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">CAMBRIDGE, Mass.<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">June 5, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Regor Therapeutics Group, a clinical-stage global biopharmaceutical company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on\u00a0Thursday, June 13. Dr. <span class=\"xn-person\">Xiayang Qiu<\/span>, Founder and CEO, will represent the Company in a session scheduled at <span class=\"xn-chron\">11:20 am (Eastern Time)<\/span> on <span class=\"xn-chron\">June 13<\/span>.<\/p>\n<p><strong>About Regor Therapeutics Group<\/strong><\/p>\n<p>Regor Therapeutics Group (&#8220;Regor&#8221;) is founded in 2018 by a team of scientists with a proven track record in drug discovery and executive leadership covering full cycle of drug discovery and development. By leveraging its industry-leading core strength in rCARD\u2122 (Computer Accelerated Rational Discovery), Regor has completed 8 PCCs inhouse, with 5 INDs filed, validating Regor&#8217;s highly efficient ecosystem for accelerated discovery of innovative therapeutic agents.<\/p>\n<p>Regor&#8217;s in-house pipeline encompasses leading assets in metabolism, oncology and auto-immunity, with two leading assets: 1) RGT-075, an orally bioavailable small molecule GLP1R full agonist with best-in-class potential for obesity &amp; beyond; and 2) RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+\/HER2- breast cancer patients.<\/p>\n<p>With a strong focus on excellence in pharmaceutical research and global competitiveness, Regor aspires to build a world-class innovation engine that promotes a winning culture of scientific excellence, strong teamwork driven by results and delivery with shared accountability and successes.<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-3692","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/3692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3692"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/3692\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}